Impact of treatment prior to allogeneic transplantation of hematopoietic stem cells in patients with myelodysplastic syndrome: results of the latin american bone marrow transplant registry
The role of bridging therapy with intensive chemotherapy and/or hypomethylating agents followed by hematopoietic stem cell transplantation (HSCT) has been suggested, but there is some controversy regarding the influence of treatment response on transplant outcomes1. Considering this context, here we have investigated the influence of treatment prior to HSCT in patients with MDS. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 27, 2020 Category: Hematology Authors: Fernando Barroso Duarte, Anna Thawanny Gadelha Moura, Vaneuza Ara újo Moreira Funke, Virgílio Antônio Rensi Colturato, Nelson Hamerschlak, Neysimélia Costa Vilela, Luiz Fernando Lopes, Maria Cristina Martins de Almeida Macedo, Afonso Celso Vigorito, R Tags: Brief Article Source Type: research

Dietary intake and Diet Quality of Hematopoietic Stem Cell Transplant Survivors
Hematopoietic stem cell transplantation (HCT) is potentially a curative treatment option for variety of hematologic diseases. Advances in the field of HCT over the past decade due to safer conditioning regimens, better post-transplant supportive care, and alternative graft sources has markedly increased the number of transplants performed leading to increases in long-term survivors. There were 108,900 HCT survivors in United States in 2009 (67,000 autologous HCT and 41,900 allogeneic HCT survivors) [1]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 24, 2020 Category: Hematology Authors: Nosha Farhadfar, Debra L. Kelly, Lacey Mead, Shalini Nair, James Colee, Vivian G. Irizarry, Hemant S. Murthy, Randy A. Brown, John W. Hiemenz, Jack W. Hsu, William S. May, John R. Wingard, Wendy J. Dahl Source Type: research

Frequency, risk factors and outcome of active tuberculosis following allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an established treatment for hematological malignancies and nonmalignant diseases. Furthermore, haploidentical stem cell transplantation has been developed in the past two decades as another potential strategy for patients with no HLA-matched donor. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 24, 2020 Category: Hematology Authors: Qiao-Zhu Zeng, Yuan-Yuan Zhang, Ye-Jun Wu, Zhuang-Yi Zhang, Jia-Ning Zhang, Hai-Xia Fu, Jing-Zhi Wang, Feng-Rong Wang, Chen-Hua Yan, Xiao-Dong Mo, Yu Wang, Yu-Hong Chen, Ying-Jun Chang, Lan-Ping Xu, Kai-Yan Liu, Xiao-Jun Huang, Xiao-Hui Zhang Source Type: research

Detection and monitoring of lineage-specific chimerism by digital droplet PCR-based testing of deletion/insertion polymorphisms
Molecular monitoring of hematopoietic chimerism is an important part of the routine diagnostic program in patients after allogeneic stem cell transplantation (SCT). Common employment of reduced-intensity conditioning (RIC) regimens and cord blood (CB) transplants, which require very careful surveillance of the graft, has further increased the clinical importance of chimerism analysis [1,2]. Chimerism testing facilitates early prediction and documentation of successful engraftment, and permits early risk assessment for impending graft failure or rejection [3-9]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 21, 2020 Category: Hematology Authors: Michaela Fortschegger, Sandra Preuner, Dieter Printz, Anna R. Poetsch, Ren é Geyeregger, Herbert Pichler, Anita Lawitschka, Thomas Lion Source Type: research

A single center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplant (HCT)
Hematopoietic cell transplantation (HCT) is associated with a high risk of invasive fungal infections (IFI). Fluconazole is approved in the United States for Candida prophylaxis during HCT, but it does not provide coverage against molds [1]. Voriconazole, a broad-spectrum triazole active against Candida and Aspergillus species, has been increasingly used for antifungal prophylaxis for high risk HCT such as cord blood HCT and ex vivo T-cell depleted HCT recipients [2 –4]. In a randomized trial of voriconazole versus fluconazole prophylaxis in standard risk HCT recipients, the overall rates of IFI and fungal free survi...
Source: Biology of Blood and Marrow Transplantation - February 20, 2020 Category: Hematology Authors: Anat Stern, Yiqi Su, Yeon Joo Lee, Susan Seo, Brian Shaffer, Roni Tamari, Boglarka Gyurkocza, Juliet Barker, Yael Bogler, Sergio Giralt, Miguel Perales, Genovefa A. Papanicolaou Source Type: research

Improved outcomes after allogenic hematopoietic stem cell transplantation with Fludarabine/Treosulfan for patients with myelodysplastic syndromes
Allogeneic hematopoietic stem cell transplantation (allo HCT) is the only known potentially curative treatment for myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). However, outcomes are generally poor, with a significant risk of relapse or transplant-related mortality. Prognosis for transplanted MDS patients can be delineated by widely used clinical scores such as the Revised International Scoring System (IPSS-R). Overall survival (OS) at 5 years post transplantation ranges from 23% to 71% for patients with very-high and very-low risk IPSS-R scores, respectively [1]. (Source: Biology of Blood and...
Source: Biology of Blood and Marrow Transplantation - February 20, 2020 Category: Hematology Authors: Eileen Wedge, Henrik Sengel øv, Jakob Werner Hansen, Niels Smedegaard Andersen, Ida Schjoedt, Soeren Lykke Petersen, Brian Kornblit, Kirsten Grønbæk, Lone Smidstrup Friis Source Type: research

Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors
The availability of unrelated donors has allowed a significant increase in the numbers of allogeneic transplants. Peripheral blood stem cells (PBSC) has become the most common hematopoietic cell graft source in unrelated donors [1]. This is likely due to perceived decreased donor discomfort and increased donor convenience compared to bone marrow harvests [2]. Currently, the most common method for collecting PBSC in unrelated donors in the U.S. is by filgrastim (Neupogen ®, Amgen, Thousand Oaks, CA, USA) mobilization and apheresis. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 20, 2020 Category: Hematology Authors: Jack W. Hsu, Bronwen E. Shaw, Soyoung Kim, Brent R. Logan, Jennifer A. Sees, Dennis L. Confer, Michael A. Pulsipher, Nirali Shah, Galen E. Switzer, Muneer H. Abidi, Ibrahim A. Ahmed, Paulo N. Anderlini, Christopher Bredseon, Saurabh Chhabra, Christopher E Source Type: research

Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery
Chimeric antigen receptor (CAR) T cell therapy has shown promising responses in various hematological malignancies and is set to lead the way for the era of adoptive T cell therapy in these type of malignancies1-9. CARs are genetically engineered surface receptors consisting of an extracellular antigen-binding domain that recognizes a specific tumor antigen, intracellular T cell signaling domains i.e. CD3zeta, and co-stimulatory molecules such as CD28 and 4-1BB10. When incorporated on autologous T cells, CARs redirect the specificity and function of T cells, that are hence able to recognize specific tumor antigens independ...
Source: Biology of Blood and Marrow Transplantation - February 20, 2020 Category: Hematology Authors: Victoria Gutgarts, Tania Jain, Junting Zheng, Molly A. Maloy, Josel D. Ruiz, Martina Pennisi, Edgar A. Jaimes, Miguel-Angel Perales, Insara Jaffer Sathick Source Type: research

Improving quality of life in hematopoietic stem cell transplant survivors through a positive psychology intervention
For some patients with advanced hematologic malignancies, non-malignant diseases and bone marrow failure syndromes, hematopoietic stem cell transplantation (HSCT) provides a potential for cure.1 Approximately 50,0002,3 HSCTs are performed worldwide and the number of transplants is projected to increase significantly in the next decade.4,5 Although recent advances in transplantation medicine have improved the morbidity and mortality following HSCT, the transplantation process is intensive and prior studies show a higher risk of treatment-related sequelae (e.g., cardiac disease, secondary malignancies, chronic graft vs. (Sou...
Source: Biology of Blood and Marrow Transplantation - February 20, 2020 Category: Hematology Authors: Hermioni L. Amonoo, Chareeni Kurukulasuriya, Kate Chilson, Lynn Onstad, Jeff C. Huffman, Stephanie J. Lee Source Type: research

T-cell depleted haploidentical hematopoietic stem cell transplantation for patients with familial hemophagocytic lymphohistiocytosis who do not have matched family donors: Experience in Oman
Familial Hemophagocytic Lymphohistiocytosis (FHLH) is a fatal disorder of immune regulation that is curable only by allogeneic hematopoietic stem cell transplantation (HSCT) [1]. With high rates of consanguineous marriage, incidence of FHLH is higher in Oman compared to other parts of the world [2]. After the initial phase of chemotherapy, patients continue on maintenance chemotherapy of etoposide, pulse dexamethasone, and cyclosporine until they go for transplantation. For a substantial number of patients, HLA matching family donors are not available, thus an alternative source of stem cells is crucial. (Source: Biology o...
Source: Biology of Blood and Marrow Transplantation - February 20, 2020 Category: Hematology Authors: Hanan F. Nazir, Fatma S. Ba Alawi, Saif Al Hosni, Abdulhakim Al Rawas, David Dennison Source Type: research

Comparison of outcomes of myeloablative allogeneic stem cell transplantation for pediatric patients with bone marrow failure, myelodysplastic syndrome and acute myeloid leukemia with and without germline GATA2 mutations
Pediatric myelodysplastic syndromes (MDS) represent a spectrum of rare hematopoietic stem cell disorders characterized by cytopenias, ineffective hematopoiesis, marrow dysplasia and risk for leukemic transformation. While some cases are likely acquired due to de novo transformation, germline mutations in DNA repair pathways, ribosomal pathways, the telomere complex or in hematopoietic transcription factors (e.g., CEBPA, RUNX1, GATA2 and ETV6) are predisposition syndromes underlying many pediatric cases of MDS and acute myeloid leukemia (AML). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 20, 2020 Category: Hematology Authors: Inga Hofmann, Serine Avagyan, Alyssa Stetson, Dongjing Guo, Hasan Al-Sayegh, Wendy B. London, Leslie Lehmann Source Type: research

Influence of the insertion site on central venous catheter-related complications in patients undergoing allogeneic hematopoietic cell transplantation
Non-tunneled central venous catheters (CVC) are routinely used in patients undergoing allogeneic hematopoietic cell transplantation (HCT) at many centers. CVC serve as venous access for fluid infusions, blood transfusions, the conditioning therapy, the stem cell product, antimicrobial therapy, parenteral nutrition and blood sampling. Thus, CVC are required to last for several weeks during the acute inpatient phase of the HCT process. However, CVC carry a major risk of catheter-related infections, leading to increased morbidity and mortality. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 18, 2020 Category: Hematology Authors: Daniela Heidenreich, Eleonore Hansen, Sebastian Kreil, Florian Nolte, Mohamad Jawhar, Anna Hecht de Gutierrez, Wolf-Karsten Hofmann, Stefan A. Klein Source Type: research

Analysis of Whole CDR3 TCR Repertoire after Hematopoietic Stem Cell Transplantation in Two Clinical Cohorts
Allogenic hematopoietic stem cell transplant (HSCT) is a potentially curative therapy for bone marrow disorders and cancers. It is the graft-versus-leukemia effect exerted by alloreactive T cells that drives this process. However, a major cause of morbidity in these patients is GVHD, which is when the balance of alloreactive T cells tips too far to attack host cells [1, 2]. Corticosteroids are the first line of therapy but less than 50% of patients achieve a lasting response [3]. Patients non-responsive to steroids require additional therapies with little to no benefit. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 18, 2020 Category: Hematology Authors: O. Shah, J.S. Tamaresis, L.J. Kenyon, L. Xu, P. Zheng, P. Gupta, K. RangarajanK, S. Lee, S. Spellman, S. Nikiforow, J. Zehnder, E.H. Meyer Source Type: research

Pilot Study of Telehealth Evaluations in Patients Undergoing Hematopoietic Cell Transplantation
Given its complexity, hematopoietic cell transplantation (HCT) requires specialized multidisciplinary care units that are often regionalized in tertiary care centers in urban or metropolitan areas [1]. The treatment process involves initial referral to a transplant center, which may be located far from the patient's place of residence, followed by extensive pre-HCT evaluation, inpatient treatment, and intensive post-HCT outpatient monitoring. As a result, HCT patients face a significant ‘burden of therapy’ with regards to time commitment and travel that can be disruptive to their lives, particularly for those w...
Source: Biology of Blood and Marrow Transplantation - February 15, 2020 Category: Hematology Authors: Mariam T. Nawas, Heather J. Landau, Craig S. Sauter, Catherine A. Featherstone, Sheila A. Kenny, Elizabeth S. Rodriguez, Lauren G. Johnson, Sergio A. Giralt, Michael Scordo Source Type: research

Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapse/refractory Hodgkin lymphoma: Real-life experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)
Most patients suffering from classical Hodgkin's lymphoma (cHL) can be treated successfully with standard chemo- and/or radiotherapy, with 70% of them being alive 10 years after diagnosis. The gold standard treatment for patients that fail first-line treatment is high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation (autoHSCT).1-4 Patients who fail autoHSCT (or at least two prior lines of therapy) may be treated with brentuximab vedotin (Bv); however, in many patients the disease will progress, with a median overall survival (OS) of approximately 22 months. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 14, 2020 Category: Hematology Authors: Carmen Mart ínez, Cecilia Carpio, Inmaculada Heras, Eduardo Ríos-Herranz, Joan Buch, Antonio Gutierrez, Samuel Romero, Izaskun Zeberio, Irene García-García, Antonia Rodriguez-Izquierdo, Rosalía Alonso, Joan Bargay, Cristina Barrenetxea, Eva Domingo-D Source Type: research

Matched-pair analysis of transplant from haploidentical, unmanipulated bone marrow donor versus hla identical sibling for patients with hematological malignancies
For many years, the main alternative for patients lacking an HLA-matched family donor has been an 8/8 HLA antigen matched unrelated donor (MUD) allocated through the International Registries of volunteer donors.1,2 However, despite the number of such volunteers exceeds 30 million,3,4 almost two thirds of patients do not proceed to transplantation. The enormous variability of HLA polymorphisms and the time required for identifying a suitable donor are the two most important factors limiting the use of MUD transplant, especially for patients at high risk of disease progression who are in urgent need of being transplanted. (S...
Source: Biology of Blood and Marrow Transplantation - February 14, 2020 Category: Hematology Authors: William Arcese, Raffaella Cerretti, Loredana Sarmati, Laura Cudillo, Gottardo De Angelis, Benedetta Mariotti, Antoine Bruno, Ilaria Mangione, Cristina Rapanotti, Marco Andreani, Paolo De Fabritiis, Teresa Dentamaro, Luca Cupelli, Andrea Mengarelli, France Source Type: research

The Role of Donor Lymphocyte Infusion (DLI) in Post Hematopoietic Cell Transplant (HCT) Relapse for Chronic Myeloid Leukemia (CML) in the Tyrosine Kinase Inhibitor (TKI) Era
The optimal approach to patients with chronic myeloid leukemia (CML) that relapse following allogeneic hematopoietic cell transplantation (HCT) in the tyrosine kinase inhibitors (TKIs) era is unknown. Imatinib was introduced in 2001 being followed by the introduction of second generation TKIs such as dasatinib or nilotinib, in subsequent years [1,2]. In later years, the spectrum of TKIs has further broadened, given the introduction of bosutinib and ponatinib [3,4]. Nevertheless, allogeneic HCT remains an important rescue strategy for some CML patients at adverse risk. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 13, 2020 Category: Hematology Authors: Sarah Schmidt, Ying Liu, Zhen-Huan Hu, Kirsten M. Williams, Hillard M. Lazarus, Ravi Vij, Mohamed A. Kharfan-Dabaja, Guillermo Ort í, Peter H. Wiernik, Daniel Weisdorf, Rammurti T. Kamble, Roger Herzig, Baldeep Wirk, Jan Cerny, Ulrike Bacher, Naeem A Cha Source Type: research

Endothelial Activation and Stress Index (EASIX) at Admission Predicts Fluid Overload in Recipients of Allogeneic Stem Cell Transplantation
Allogeneic hematopoietic cell transplantation (AHCT) is a potential curative option for a variety of hematological malignancies. A number of complications occurring after AHCT can lead to an increased non-relapse mortality (NRM). Fluid overload (FO) has recently been recognized as a serious complication occurring after AHCT, associated with an increased non-relapse mortality (NRM). [1,2] Several non-transplant studies in critically ill patients have also reported decreased survival and increased hospital stay in patients who develop FO. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 9, 2020 Category: Hematology Authors: Ankur Varma, Gabriela Rondon, Samer A. Srour, Julianne Chen, Celina Ledesma, Richard E. Champlin, Stefan O. Ciurea, Rima M. Saliba Source Type: research

Long-term immunity to measles after allogeneic haematopoietic cell transplantation: factors associated with seroprotection before revaccination
Measles is a life-threatening viral infection that may occur after allogeneic haematopoietic cell transplantation (HCT), and until now, there has been no active antiviral treatment [1, 2]. After the introduction of the measles vaccine in the early 1980s, a decreased vaccinal coverage of the population was observed in many countries, leading to measles re-emergence, an increased risk of outbreaks worldwide and of the life-threatening disease appearing in immunocompromised patients. The worldwide number of measles deaths remains around 100,000 yearly [3, 4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 8, 2020 Category: Hematology Authors: Christine Robin, Alice-Andree Mariaggi, Rabah Redjoul, Mathieu Leclerc, Florence Beckerich, Ludovic Cabanne, C écile Pautas, Sébastien Maury, Flore Rozenberg, Catherine Cordonnier Source Type: research

Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplants for Relapsed/Refractory Diffuse Large B-cell Lymphoma –Is More Actually Less?
A proportion of patients with diffuse large B-cell lymphoma (DLBCL) will fail to achieve durable remissions to standard chemoimmunotherapy treatment with R-CHOP or dose adjusted R-EPOCH. [1] Of these patients who relapse, standard of care involves salvage with high-dose chemotherapy and, if remission is obtained, consolidation with autologous hematopoietic stem cell transplant (auto-HCT). [2] Many patients will not be able to achieve a remission that would facilitate eventual consolidation with auto-HCT, and of those patients that are consolidated with auto-HCT, approximately half will ultimately have recurrence of their d...
Source: Biology of Blood and Marrow Transplantation - February 8, 2020 Category: Hematology Authors: Ryan Jacobs, Nilanjan Ghosh Source Type: research

Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) in Children
Acute graft-versus-host disease (aGVHD), a major obstacle to the success of allogeneic hematopoietic stem cell transplantation (HSCT) and affects 40 –60% of patients undergoing HSCT. GVHD is also a major cause of non-relapse mortality after HSCT. [1-3] Although the management of aGVHD has improved in recent years, [4] a therapeutic gap exists in effective management of aGVHD which is refractory to steroid therapy, particularly in subjects with more severe disease, determined by grade C/D, liver and lower gastrointestinal organ involvement and/or multi-organ involvement, or high risk stratification. (Source: Biology o...
Source: Biology of Blood and Marrow Transplantation - February 7, 2020 Category: Hematology Authors: Joanne Kurtzberg, Susan Prockop, Sonali Chaudhury, Biljana Horn, Eneida Nemecek, Vinod Prasad, Prakash Satwani, Pierre Teira, Jack Hayes, Elizabeth Burke, for the MSB-275 Study Group Source Type: research

Priorities for Improving Outcomes for Non-Malignant Blood Diseases: A Report from the Blood and Marrow Transplant Clinical Trials Network
Non-malignant blood diseases such as bone marrow failure disorders, immune dysregulation disorders, and hemoglobinopathies often lead to shortened lifespans and poor quality of life. Many of these diseases can be cured with allogeneic hematopoietic cell transplantation (HCT), but patients are often not offered the procedure because of perceived insufficient efficacy and/or excess toxicity. The Blood and Marrow Transplant Clinical Trials Network (BMT CTN), which is funded by the National Heart, Lung, and Blood Institute (NHLBI) and the National Cancer Institute (NCI), is uniquely positioned to strategically prioritize and a...
Source: Biology of Blood and Marrow Transplantation - February 5, 2020 Category: Hematology Authors: John E. Levine, Joseph H. Antin, Carl E. Allen, Lauri M. Burroughs, Kenneth R. Cooke, Steven Devine, Helen Heslop, Ryotaro Nakamura, Julie An Talano, Gregory Yanik, Nancy DiFronzo Source Type: research

Permanent impairment-free, relapse-free survival: A novel composite endpoint to evaluate long-term success in allogeneic transplant
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a promising treatment procedure for patients with hematological diseases. Remarkable advances in transplantation techniques and supportive care practices have enhanced the long-term survival after allo-HCT, and transplant-related health problems affecting the quality of life have garnered considerable interest lately [1 –4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 5, 2020 Category: Hematology Authors: Yoshitaka Adachi, Kazutaka Ozeki, Shun Ukai, Ken Sagou, Nobuaki Fukushima, Akio Kohno Source Type: research

Letermovir for secondary prophylaxis of CMV infection and disease after allogeneic hematopoietic cell transplantation: Results from the French compassionate program
After allogeneic HCT, CMV infection and disease impair survival [1,2]. Letermovir potently inhibits the CMV-terminase complex. In a large phase III trial [3], letermovir as a primary prophylaxis (PP) has been shown to reduce clinically significant CMV infection after allogeneic HCT and to have a favourable safety profile comparable to placebo. Moreover, a post-hoc analysis showed that letermovir reduces all-cause mortality in patients with clinically significant CMV infection through Week 48 when compared with a placebo and when adjusted for CMV-risk status [4]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 5, 2020 Category: Hematology Authors: Christine Robin, Anne Thiebaut, Sophie Alain, Flore Sicre de Fontbrune, Ana Berceanu, Maud D'Aveni, Patrice Ceballos, Rabah Redjoul, St éphanie Nguyen-Quoc, Nathalie Bénard, Golriz Pahlavan-Grumel, Catherine Cordonnier Source Type: research

Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage-Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
With the currently available upfront chemotherapy regimens, majority of adult patients with B cell acute lymphoblastic leukemia (B-ALL) achieve a complete remission (CR). However, due to high rates of relapse,1-5 especially in the high-risk groups, long-term overall survival (OS) for these patients remains low.6,7 Poor outcomes after standard chemotherapy alone could be explained by i) disease-related factors such as increased frequency of high-risk mutations,8 and lack of good-risk cytogenetics 9 and ii) patient-related factors such as age and comorbid conditions limiting the use of more intensive adolescent/young adult (...
Source: Biology of Blood and Marrow Transplantation - February 5, 2020 Category: Hematology Authors: Amandeep Salhotra, Dongyun Yang, Sally Mokhtari, Monzr M. Al Malki, Haris Ali, Karamjeet S. Sandhu, Ahmed Aribi, Samer Khaled, Matthew Mei, Elizabeth Budde, David Snyder, Thai Cao, Ricardo Spielberger, Guido Marcucci, Vinod Pullarkat, Stephen J. Forman, R Source Type: research

Systematic Review of Patient-Reported Outcome Measures in Graft-versus-Host-Disease
Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after hematopoietic stem cell transplant (HSCT). Traditionally, GVHD was defined as acute and chronic based on time post-transplant, but more recently the 2 are distinguished by clinical and pathophysiologic features [1,2]. GVHD can affect individual organs or can be pleiotropic and can have profound impact on health-related quality of life (QOL) [3]. Chronic GVHD (cGVHD) has been associated with poor functional status, inability to return to work, disrupted activities of daily living, and increased symptom burden [4-6]. (Source: Biology of Blood ...
Source: Biology of Blood and Marrow Transplantation - February 3, 2020 Category: Hematology Authors: James Kilgour, Gorav Wali, Elizabeth Gibbons, Angela Scherwath, Anna Barata Badiella, Andy Peniket, Helene Schoemans, Rubeta N. Matin, in collaboration with the cGVHD Eurograft Network Source Type: research

A Systematic Review of Patient Reported Outcome Measures in Graft-versus-Host-Disease (GVHD)
Graft-versus-host disease (GVHD) is a major cause of morbidity and mortality following haematopoietic stem cell transplantation (HSCT). Traditionally, GVHD was defined as acute and chronic based on time post-transplantation, but more recently, the two are distinguished by clinical and pathophysiological features [1,2] GVHD can affect individual organs or be pleiotropic, and can have profound impact on health-related quality of life (HRQOL) [3]. Chronic GVHD has been associated with poor functional status, inability to return to work, disrupted activities of daily living, and increased symptom burden [4-6]. (Source: Biology...
Source: Biology of Blood and Marrow Transplantation - February 3, 2020 Category: Hematology Authors: Dr James Kilgour, Dr Gorav Wali, Ms Elizabeth Gibbons, Dr Angela Scherwath, Dr Anna Barata Badiella, Dr Andy Peniket, Dr Helene Schoemans, Dr Rubeta N. Matin Source Type: research

A Systematic Review of Sodium Disorders in HHV-6 Encephalitis
HHV-6 is the collective name of two distinct viral species, HHV-6A and HHV-6B, both members of the subfamily betaherpesvirinae, which also includes cytomegalovirus (CMV) and HHV-7. Seropositivity to HHV-6 is greater than 95% in adults in developed countries1 with nearly 80% acquiring the virus by the age of 2 years.2 Of the two species, HHV-6B makes up the vast majority of symptomatic primary infections in infants 3 and is the causative agent of exanthema subitum, also known as roseola infantum. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 3, 2020 Category: Hematology Authors: NikolasC. Victoria, TuanL. Phan, KrishnaA. Agarwal Source Type: research

A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to Respond to Steroid Treatment for Acute Graft-versus-Host Disease
Acute graft-versus-host disease (aGVHD) is a major obstacle to the overall success of allogeneic hematopoietic stem cell transplantation (HSCT). Although the incidence of aGVHD varies across transplant type and donor sources, severe aGVHD (determined by grade C/D, visceral organ and/or multiorgan involvement, or high-risk stratification) is associated with the highest risk of primary treatment failure and highest transplant-related mortality [1,2]. Mortality can reach as high as 90% in adults and children who fail to respond to initial steroid therapy [2-5]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2020 Category: Hematology Authors: Joanne Kurtzberg, Hisham Abdel-Azim, Paul Carpenter, Sonali Chaudhury, Biljana Horn, Kris Mahadeo, Eneida Nemecek, Steven Neudorf, Vinod Prasad, Susan Prockop, Troy Quigg, Prakash Satwani, Annie Cheng, Elizabeth Burke, Jack Hayes, Donna Skerrett, for the Source Type: research

A Phase 3, Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients who Failed to Respond to Steroid Treatment for Acute GVHD
Acute graft-versus-host disease (aGVHD) is a major obstacle to the overall success of allogeneic hematopoietic stem cell transplantation (HSCT). Although the incidence of aGVHD varies across transplant type and donor sources, severe aGVHD (determined by grade C/D, visceral organ and/or multi-organ involvement, or high risk stratification) is associated with the highest risk of primary treatment failure and highest transplant related mortality [1,2]. Mortality can reach as high as 90% in adults and children who fail to respond to initial steroid therapy [2 –5]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2020 Category: Hematology Authors: Joanne Kurtzberg, Hisham Abdel-Azim, Paul Carpenter, Sonali Chaudhury, Biljana Horn, Kris Mahadeo, Eneida Nemecek, Steven Neudorf, Vinod Prasad, Susan Prockop, Troy Quigg, Prakash Satwani, Annie Cheng, Elizabeth Burke, Jack Hayes, Donna Skerrett, for the Source Type: research

Enterococcus: A predictor of ravaged microbiota and poor prognosis after allogeneic hematopoietic stem cell transplantation
The human intestinal flora comprises over 100 trillion microorganisms and plays a significant role in host survival. Several reports have suggested the relationship between dysbiosis of the gut microbiota and the pathogenesis of various immune diseases, via metagenomic analysis targeting the 16S rRNA of intestinal bacterial flora. In addition, changes in gut flora are associated with poor prognosis after allogeneic hematopoietic stem cell transplantation (HSCT) [1, 2], the occurrence of graft versus host disease (GVHD) [3, 4], and the risk of bloodstream infections [2, 5, 6]. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2020 Category: Hematology Authors: Shinsuke Kusakabe, Kentaro Fukushima, Takafumi Yokota, Akihisa Hino, Jiro Fujita, Daisuke Motooka, Shota Nakamura, Hirohiko Shibayama, Yuzuru Kanakura Source Type: research

Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation
Allogeneic stem cell transplantation (allo-SCT) is the only curative treatment option for many hematological diseases, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Outcomes of allo-SCT have improved with better supportive care, reduced intensity conditioning regimens, and use of alternative stem cell donor sources. [1] However, relapsed disease after allo-SCT remains a major cause of treatment failure, occurring in approximately 40% of AML cases, most of which occur within the first year. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - February 1, 2020 Category: Hematology Authors: Amy Y. Wang, Justin Kline, Wendy Stock, Satyajit Kosuri, Andrew Artz, Richard A. Larson, Peter A. Riedell, Michael Bishop, Hongtao Liu Source Type: research

Features of Cytomegalovirus DNAemia Blips in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Implications for Optimization of Preemptive Antiviral Therapy Strategies
Cytomegalovirus (CMV) infection continues to be a clinically relevant problem in allogeneic hematopoietic stem cell transplant recipients (allo-HSCT) [1]. Preemptive antiviral therapy (PET) triggered upon detection of CMV DNA in the blood compartment has long been the first-choice strategy for prevention of CMV disease in this setting [1]. How this strategy will be positioned in the management of CMV infection in the new era of letermovir prophylaxis [2,3] remains to be established. Neither is there consensus on the CMV DNA load threshold that should prompt initiation of PET, nor on whether this cut-off should be adapted a...
Source: Biology of Blood and Marrow Transplantation - January 30, 2020 Category: Hematology Authors: Dixie Huntley, Alberto Talaya, Estela Gim énez, Ariadna Martínez, Juan Carlos Hernández-Boluda, Rafael Hernani, Ignacio Torres, Juan Alberola, Eliseo Albert, José Luis Piñana, Carlos Solano, David Navarro Source Type: research

Goal-oriented monitoring of cyclosporine is effective for graft-versus-host disease prevention after Hematopoietic Stem Cell Transplantation in Sickle Cell Disease and Thalassemia major
Thalassemia major (TM) and sickle cell anemia (SCA) are the two most widespread inborn hemoglobinopathies worldwide. TM was the first congenital hemoglobinopathy to be cured by allogenic hematopoietic stem cell transplantation (HSCT),1 and SCA rapidly followed.2,3 Other than gene therapy,4 HSCT remains the only available curative treatment for these two diseases. Provided that an HLA-identical sibling donor is available, it should be performed as soon as possible for TM and in case of complications for SCA. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 30, 2020 Category: Hematology Authors: Alexandra Gauthier, Nathalie Bleyzac, Nathalie Garnier, Kamila Kebaili, Philippe Joly, Marie-Pierre Goutagny, Isabelle Mollet, Sylvain Goutelle, C écile Renard, Yves Bertrand Source Type: research

Nilotinib treatment of patients affected by chronic graft-versus-host disease reduces collagen production and skin fibrosis by down-modulating the TGF- β and p-SMAD pathway.
Chronic Graft-Versus-Host Disease (cGVHD), a major complication of allogeneic stem cell transplantation (allo-HCT), is an immune-mediated disease resulting from a complex interaction between donor and recipient adaptive immunity, leading to reduced patient-reported quality of life and non-relapse mortality1,2. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 29, 2020 Category: Hematology Authors: Marinelli Busilacchi Elena, Costantini Andrea, Mancini Giorgia, Tossetta Giovanni, Olivieri Jacopo, Poloni Antonella, Viola Nadia, Butini Luca, Campanati Anna, Goteri Gaia, Marzioni Daniela, Attilio Olivieri Source Type: research

Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for many malignant and nonmalignant hematologic disorders [1,2]. Although matched-related donor (MRD) and matched-unrelated donor (MUD) are considered the ideal sources of hematopoietic stem cells, many patients lack timely access to a suitable matched donor, especially in the context of aggressive diseases. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 28, 2020 Category: Hematology Authors: Chiara Oltolini, Raffaella Greco, Laura Galli, Daniela Clerici, Francesca Lorentino, Elisabetta Xue, Maria Teresa Lupo Stanghellini, Fabio Giglio, Lina Uhr, Marco Ripa, Paolo Scarpellini, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Antonella Casta Source Type: research

Infections after allogenic transplant with post-transplant cyclophosphamide: impact of donor HLA-matching
Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for many malignant and non-malignant hematological disorders [1,2]. Although matched-related donor (MRD) or matched-unrelated donor (MUD) are considered the ideal sources of hematopoietic stem cells, many patients lack timely access to a suitable matched-donor, especially in the context of aggressive diseases. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 28, 2020 Category: Hematology Authors: Chiara Oltolini, Raffaella Greco, Laura Galli, Daniela Clerici, Francesca Lorentino, Elisabetta Xue, Maria Teresa Lupo Stanghellini, Fabio Giglio, Lina Uhr, Marco Ripa, Paolo Scarpellini, Massimo Bernardi, Consuelo Corti, Jacopo Peccatori, Antonella Casta Source Type: research

Initiating the Conversation of Oncofertility: The Creation of a Dedicated BMT Oncofertility Nurse Coordinator in the Transplant and Cellular Therapy Patient Population
Patients undergoing hematopoietic stem cell transplantation face a high risk of infertility. Despite existing ASCO, ASRM and NCCN fertility preservation guidelines, as many as 68% of oncology patients report that fertility was not discussed prior to or during therapy. Since infertility in survivorship is known to increase distress and contribute to decreased quality of life, upfront oncofertility discussions must be more embedded into our programmatic education. To increase the prevalence and depth of fertility preservation counseling among Blood and Marrow Transplant (BMT) and cellular therapy patients, the BMT oncofertil...
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Kara Armato, Erin Winters, Caroline Strohm, Liza Rodriguez, Joanne Wilson, Joseph P. McGuirk Tags: 112 Source Type: research

Admit in Confidence: Implementing a Pre-Admission Phone Screening for Hematopoietic Stem Cell Transplant
According to UpToDate, “active infections in the hematopoietic stem cell transplant (HSCT) candidate should be eliminated prior to transplantation.” HSCT causes immune deficiency meaning even asymptomatic infections can turn into sepsis following transplant. Our nursing team recognized a trend of delaying transplants or discharging a patient on admission due to infection. There was a clear need for a standardized, pre-admission screening for HSCT.The purpose of this study was to see how a standardized, pre-admission phone screening effected HSCT delays or cancellations on a 16-bed in-patient HSCT unit in an aca...
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Andrea Wagner, Sarah Gerber, Janel Joaquin, Kevin McNamara, Edgar Rey Tags: 113 Source Type: research

Assessing the Relationship between Glasgow Coma Scale Scores and MS Documentation in Allogeneic Hematopoietic Cell Transplant Recipients with Suspected Infection
Sepsis leads to physiologic shock, organ dysfunction and death. Mental status (MS) changes are known indicators of sepsis, so clinical criteria that measure awareness and mentation have been incorporated in sepsis screening tools such as the quick Sequential Organ Failure Assessment (qSOFA). To evaluate the utility of GCS as a MS assessment tool, we examined the relationship between GCS scores and MS clinical record documentation in allogeneic hematopoietic cell transplant (aHCT) recipients with suspected infections (SI). (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Mirta J. Maravilla-Rosas, Lindsay McFarland, Lenise Taylor, Sandra Kei Olson, Steven A. Pergam, Margaret L Lind Tags: 114 Source Type: research

Preparing Nurses on an Intermediate Care Unit to Assess and Manage Patients Undergoing Chimeric Antigen Receptor Therapy (CAR T) at an NCI Designated Academic Cancer Center
Chimeric Antigen Receptor Therapy (CAR T) is a dynamic rapidly developing area of cancer treatment. The delivery of this therapy is complex and many centers struggle with operationalizing the various phases of this treatment, including which specialty area is best equipped to administer, monitor and safely manage the patient for potentially life threatening side effects during each phase of therapy. Without a dedicated CAR T service, it was the determined that adult patients receiving this treatment would be best managed on our intermediate care leukemia/lymphoma unit. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Joey Misuraca, Jennifer Frith, Martha Lassiter, Nicola Brooksbank, Krista Rowe Nichols Tags: 115 Source Type: research

Delivering Post Hematopoietic Stem Cell Transplant (HSCT) Vaccines in a Pediatrician's Office Versus Specialty Care Setting
Children undergoing hematopoietic stem cell transplant (HSCT) lose their prior immunity post-allogeneic transplant and need reimmunization post-transplant. Traditionally, immunizations post-HSCT were administered at a pediatrician's office (PO), but studies in adult patients have shown compliance with re-vaccination to be low and no data exists on adherence in pediatrics. An internal audit of HSCT patients who received vaccinations at a PO revealed delays in starting vaccines when eligible, non-completion of the schedule in its entirety happened often, and there was an extended length of time for completion of the schedule...
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Ellen Levy, Anne Wohlschlaeger, Megan Atkinson, Nancy Bunin, Caitlin W. Elgarten, Brian T. Fisher, Stephan A. Grupp, Patricia Hankins, Jennifer Heimall, Raabia Khan, Talene Metjian, Timothy S. Olson, Houston Roberson, Jason L. Freedman Tags: 106 Source Type: research

Effects of Oral Cryotherapy Treatment on Oral Mucositis in Patients Receiving Busulfan Chemotherapy: A Retrospective/Prospective Descriptive Study
Two chemotherapeutic agents used in blood and marrow transplant (BMT) conditioning regimens, melphalan and busulfan, are known for their high rates of oral mucositis (OM). While there is extensive literature on the effects of oral cryotherapy (OC) with melphalan, there is limited literature on its effects with busulfan. The aim of this study was to determine if OC decreases busulfan-associated OM. The secondary aim of this study was to look at the effects OC with busulfan had on length of stay (LOS), intensive care unit (ICU) transfer for airway protection, total parenteral nutrition (TPN) use, and opioid use for OM. (Sour...
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Azure Grossman, Nicholas Koch, Nancy Froggatt, Melinda Kannenberg, Dean Pitcher, Kelli Reid, Peter Bullock, Jolie Neubauer, Lauren Hendricks, Kathryn A. Lochmann Tags: 107 Source Type: research

A Single Dose of a Novel Anti-Human Short Half-Life Engineered CD45-Targeted Antibody-Drug Conjugate (ADC) Is Cytoreductive on Patient-Derived Tumors and Extends Survival Beyond Standards of Care in Multiple Pre-Clinical Models of Hematologic Malignancy
For patients with refractory or high-risk hematologic malignancies, like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and acute lymphoblastic leukemia (ALL), allogeneic hematopoietic stem cell transplant (Allo-HSCT) is a potentially curative approach. Morbidities and mortality associated with current conditioning regimens limit the use of this curative procedure. As a result, many eligible patients do not consider transplant and 2/3 of those transplanted are only able to tolerate a reduced intensity conditioning regimen, which is associated with increased relapse rates (Scott, J Clin Onc 2017). (Source: B...
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Jennifer L. Proctor, Geoffrey O. Gillard, Oliver Mikse, Leanne Lanieri, Tahirih L. Lamothe, Melissa L. Brooks, Lena Kien, Sean M. McDonough, Anjali Bhat, Rahul Palchaudhuri, Prashant raj Bhattarai, Ganapathy N. Sarma, Nidhi Jain, Charlotte F. McDonagh, An Tags: 128 Source Type: research

Chimeric Antigen Receptor T Cell Therapy for Acute Myeloid Leukemiachimeric Antigen Receptor T Cell Therapy for Acute Myeloid Leukemia
Relapse of leukemic cells that do not express the antigen targeted by chimeric antigen receptor (CAR) is still a risk. As is the potential for targeting hematopoietic stem cells (HSCs) that share the same antigen expression, off-tumor on-target toxicity. Further, CAR T cells that bind different epitopes of the same antigen can have different tumor-killing efficacies. Therefore, we screen murine single chain variable fragment (scFv) based for indirect affinity to identify a CAR that targets Acute myeloid leukemia (AML), while minimizing toxicities. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Bishwas Shrestha, Paresh Vishwasrao, Gongbo Li, Tayyebb Ghafoor, Marco L. Davila Tags: 129 Source Type: research

Human pSTAT3-Inhibited Itregs Prevent Gvhd, Maintain Anti-Leukemia Immunity, and Increase Their Potency after Metabolic Reprogramming
Immune suppressive donor regulatory T cells (Tregs) can be expanded to prevent or treat graft-versus-host disease (GVHD). In human induced Tregs (iTregs), we demonstrated that inhibiting STAT3 phosphorylation (pSTAT3) with S3I-201 increases demethylated Foxp3 and significantly improves their suppressive potency in vitro, mitigating phenotypically plastic iTreg de-differentiation. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Kelly Walton, Mario R. Fernandez, Elizabeth M. Sagatys, Jordan Reff, Jongphil Kim, Marie C. Lee, John V. Kiluk, Nicholas J. Lawrence, Harshani R. Lawrence, Joseph A. Pidala, Steven Z. Pavletic, Bruce R. Blazar, Said M. Sebti, John L Cleveland, Claudio Ana Tags: 238 Source Type: research

Recovery of Innate Lymphoid Cells after Allogeneic Stem Cell Transplant in a Pediatric Population: A Single Institution Pilot Study.
Innate lymphoid cells (ILCs) are a subset of innate immune cells that mimic the functions of T lymphocytes, but lack rearranged antigen receptors or clonal expansion in response to antigens. They are characterized in human peripheral blood as Lin − (CD3, CD1a, CD4, CD14, CD16, CD19, CD34, CD94, CD303, FceRI) CD127+ cells. ILCs are divided into three sub-groups: ILC type 1, 2 and 3. The recovery of these cells after allogeneic hematopoietic stem cell transplant (aHSCT) in the pediatric population has not been described. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Anand Srinivasan, David F. Crawford, Crystal Gazaway, Megan Blanton, Lauren Acklin, Rachel Posey, Sandra Bajana, Carrie Yuen, Xiao-Hong Sun, Rikin K Shah Tags: 239 Source Type: research

Chemotherapy and Inflammation Induced Damage of Intestinal Epithelium Is Associated with Increased T Cell Chemotaxis
Gastro-intestinal (GI) Graft-versus-Host Disease (GvHD) involves a complex interplay of conditioning-related injury and the pathologic immune response at the epithelial level. Enhanced tissue damage is a risk factor for GVHD. We demonstrated that donor T cell-derived IFN γ causes intestinal stem cell damage in GvHD. Recent studies have proposed that donor T cells directly interact with GI epithelium in GvHD in vivo, but the precise mechanisms remain incompletely understood. Here, we evaluate the influence of both cytokine- and chemotherapy-induced intestinal epithe lial damage on T cell migration and direct epithelia...
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Suze A. Jansen, Marliek van Hoesel, Michal Mokry, Leire Saiz Sierra, Shuichiro Takashima, Edward E. Nieuwenhuis, Alan M. Hanash, Caroline A. Lindemans Tags: 240 Source Type: research

Pretransplant Short-Term Exposure of Donor Graft Cells to ITK Selective Inhibitor ONO-7790500 Prevents Acute Gvhd in Mouse BMT Model
Graft-versus-host disease (GVHD) triggered by activated donor graft cells still remains a major complication and course of non-relapse mortality after HSCT. Interleukin-2-inducible T-cell kinase (ITK) is a TEC family cytoplasmic tyrosine kinase of crucial importance for T cell development and TCR signaling. Recent studies demonstrated that ITK-deficient CD4+ T cells easily differentiated into regulatory T cells (Tregs) and ITK/BTK inhibitor ibrutinib could improve chronic GVHD symptoms in mouse model and human clinical study, suggesting that ITK may have important roles in post-transplant immune tolerance. (Source: Biology...
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Takumi Kondo, Yasuhisa Sando, Yuichi Sumii, Shuntaro Ikegawa, Hiroyuki Sugiura, Makoto Nakamura, Miki Iwamoto, Yusuke Meguri, Yoshinobu Maeda, Ken-ichi Matsuoka Tags: 241 Source Type: research

Dimethyl Fumarate Ameliorates Disease Severity in a Mouse Model of Chronic Graft-Versus-Host Disease.
Chronic graft-versus host disease (cGvHD) is a major complication of allogeneic hematopoietic stem cell transplantation. Standard treatment mainly consists of corticosteroids but is limited by a high percentage of steroid-refractory cases. Alloreactive T cells are a major driver of the disease, infiltrating target organs such as the liver. However, global ablation of T cells interferes with the graft-versus-leukemia effect and bears the risk of increased infections. An increased use of glycolysis has been shown to drive T cell activation and its inhibition can blunt T cell effector functions. (Source: Biology of Blood and ...
Source: Biology of Blood and Marrow Transplantation - January 24, 2020 Category: Hematology Authors: Julian C. Assmann, Kathrynne Warrick, Christopher Johns, Don E. Farthing, Ronald E. Gress, Nataliya P. Buxbaum Tags: 242 Source Type: research